A proof-of-concept study to evaluate the antiinflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 2, 2009, Pages 161-167

  Williamson, Peter A ^a,c   Menzies, Daniel ^a   Nair, Aran ^a   Tutuncu, Ahmet ^b   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Verus Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CREATININE; CYCLODEXTRIN; HYDROCORTISONE; METHACHOLINE; NITRIC OXIDE; SALBUTAMOL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; NEBULIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SUSPENSION; TREATMENT DURATION;

EID: 60849105374     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60248-7     Document Type: Article

References (30)

1. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of Asthma. Thorax. 2003;58(suppl 1):i1-i94.
2. Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50:1201-1208.
3. Investigators Bronchure: Capsitol Enabled Budesonide Inhalation Solution (CBIS). San Diego, CA: Verus Pharmaceuticals; 2006:17.
4. Wilson AM, Lipworth BJ. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med. 2000;108:269-275.
5. Fowler SJ, Orr LC, Sims EJ, et al. Therapeutic ratio of hydrofluoroal-kane and chlorofluorocarbon formulations of fluticasone propionate. Chest. 2002;122:618-623.
6. Dempsey O, Kennedy G, Lipworth B. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol. 2002;109:68-74.
7. Menzies D, Nair A, Hopkinson P, McFarlane L, Lipworth BJ. Differential anti-inflammatory effects of large and small particle size inhaled corticosteroids in asthma. Allergy. 2007;62:661-667.
8. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998;85:653-666.
9. Tsoukias NM, Shin HW, Wilson AF, George SC. A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol. 2001;91:477-487.
10. Fardon TC, Burns P, Barnes ML, Lipworth BJ. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006;96:422-430.
11. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1994;152:1107-1136.
12. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161:309-329.
13. Fardon TC, Fardon EJ, Hodge MR, Lipworth BJ. Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. Ann Allergy Asthma Immunol. 2004;93:365-372.
14. Gelb AF, Taylor CF, Nussbaum E, et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004;170:737-741.
15. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J. 2005;25:986-991.
16. Berry MA, Shaw D, Morgan A, et al. Association between alveolar nitric oxide concentration and bronchoalveolar lavage but not bronchial wash eosinophil count in patients with asthma. Thorax. 2004;59:ii50.
17. Lehtimaki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med. 2001;163:1557-1561.
18. Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest. 2007;131:1353-1362.
19. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J. 2001;18:635-639.
20. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008;31:1213-1220.
21. Robroeks CM, van de Kant KD, van Vliet D, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclometha-sone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol. 2008;100:601-607.
22. Sont JK, Willems LNA, Bel EH, van Krieken HJM, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med. 1999;159:1043-1051.
23. van Aalderen WM, Gerritsen J, Koeter GH, van der Weele LT, Postma DS, Knol K. The reproducibility and agreement of three indices of airway responsiveness to histamine in asthmatic children. Pediatr Pul-monol. 1989;6:113-117.
24. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008;372:1065-1072.
25. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med. 2007;176:231-237.
26. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:15-21.
27. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53:91-95.
28. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001;164:1376-1381.
29. Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006;129:1492-1499.
30. Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26:52-59.